New drugs in the treatment of colorectal carcinoma

Cancer

Volumn 83, Issue 4, 1998, Pages 679-689

  Punt, Cornelis J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

17 1A monoclonal antibody; 5 ethynyluracil; Capecitabine; Chemotherapy; Colorectal carcinoma; Irinotecan (CPT 11); Oxaliplatin; Raltitrexed; Review; S 1; Uracil tegafur

Indexed keywords

9 AMINOCAMPTOTHECIN; BETA INTERFERON; CAPECITABINE; EDATREXATE; EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OCTREOTIDE; OXALIPLATIN; RALTITREXED; TALLIMUSTINE; TEGAFUR; TOPOTECAN; TRIMETREXATE; UFT;

ADULT; ARTICLE; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; HUMANS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; TEGAFUR; THIOPHENES; TOPOTECAN; TRIMETREXATE; URACIL;

EID: 0031842077     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980815)83:4<679::AID-CNCR8>3.0.CO;2-F     Document Type: Article

References (115)

1. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993;29A: 2077-9.
2. The Advanced Colorectal Cancer Meta-Analysis Project: modulation of fluorouracil by leucovorin in patients with advanced CRC: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly lowdose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French inter-group study. J Clin Oncol 1997;15:808-15.
4. Sobrero AF, Aschele C, Bertino JF. Fluorouracil in colorectal cancer, a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-81.
5. Lévi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350:681-6.
6. Buyse M. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8.
7. The Advanced Colorectal Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960-9.
8. The Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
9. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994;20:73-96.
10. Hsaing YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
11. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
12. Chabot G, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995;6:141-51.
13. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, ChouTC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
14. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, et al. Pharmacokinetics and pharmacodynamics of irinotecan hydrochloride (CPT-11) during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996;14:2688-95.
15. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
16. De Forni M, Bugat R, Chabot GG, Culine S, Extra YM, Gouyette A, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994;54: 4347-54.
17. Abigerges D, Chabot GG, Armand J, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.
18. Catimel G, Chabot GG, Guastella JP, Dumortier A, Cote C, Engel C, et al. Phase I and pharmacokinetic study of irinotecan (CPT 11) administered daily for three consecutive days every three weeks in patients with advanced solid tumours. Ann Oncol 1995;6:133-40.
19. Armand JP, Extra YM, Catimel G, Abigerges D, Marty M, Clavel M. Rationale for the dosage and schedule of CPT-11 (Irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996;7:837-42.
20. Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan) - induced adverse events: the European perspective. Eur J Cancer 1996;32A(Suppl 3): S18-23.
21. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, et al. Irinotecan (CPT-11) high dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446-9.
22. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 1997;15:2910-9.
23. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of CPT-11 (irinotecan) in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with 5-FU based chemotherapy. J Clin Oncol 1997;15:251-60.
24. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993;11:909-13.
25. Von Hoff DD, Rothenberg ML, Pitot HC, Elfring GL, Mohrland JS, Schaaf LJ, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of PDA-reviewed pivotal US clinical trials [abstract]. Proc Am Soc Clin Oncol 1997;16:228a.
26. Van Cutsem E, Rougier P, Droz JP, Marty M, Bleiberg H. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU [abstract]. Proc Am Soc Clin Oncol 1997;16:268a.
27. Erlichman C, Svingen PA, Mullany SA, Kaufmann SH. Synergistic interaction of SN-38 and 5-FU/leucovorin [abstract]. Proc Am Assoc Cancer Res 1996;37:294.
28. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.
29. Vanhoefer U, Harstrick A, Muller C, Achterrath W, Kohne CH, Krauss C, et al. Phase I study of a weekly schedule of irinotecan (CPT-11) in combination with high-dose folinic acid and 5-fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:272a .
30. Ducreux M, Rougier Ph, Ychou M, Seitz JF, Bonnay M, Mignard D, et al. Phase I/II study of escalating dose of CPT-11 in combination with LV5/FU2 ("De Gramont" regimen) every two weeks in the treatment of colorectal cancer (CRC) after 5-FU failure [abstract]. Proc Am Soc Clin Oncol 1997;16:234a.
31. Rothenberg ML, Pazdur R, Rowinsky EK, Cohn AL, Alberts DS, Petit RG, et al. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated colorectal cancer (CRC) [abstract]. Proc Am Soc Clin Oncol 1997;16:266a.
32. O'Dwyer PJ, Lacreta EP, Haas NB, Halbherr T, Frucht H, Goosenberg E, et al. Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 1994; 34(Suppl):S46-52.
33. Creemers GJ, Wanders J, Gamuchi T, Vallentin S, Dirix LY, Schoffski P, et al. Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials groups. Ann Oncol 1995;6:844-6.
34. Creemers GJ, Gerrits CJH, Schellens MT, Planting AS, van den Burg ME, van Beurden VM, et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996;14:2540-5.
35. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8.
36. Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Hariold M, et al. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 1997;15:1492-501.
37. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, et al. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 1996;14:1236-44.
38. Pazdur R, Diaz-Canton E, Ballard WP, Bradof JE, Graham S, Arbuck SG, et al. Phase II trial of 9 aminocamptothecin administered as a 72 hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 1997;15:2905-9.
39. Sparreboom A, de Jonge MJA, Loos WJ, van Beurden V, Punt CJA, Planting AS, et al. Pharmacokinetics and oral bioavailability of 9-aminocamptothecin PEG1000 capsules [abstract]. Eur J Cancer 1997;33(Suppl 8):S246.
40. Kidani Y, Naji M, Tashiro T. Antitumour activity of platium II complexes of 1,2-diamino-cyclohexane isomers. Jpn J Cancer Res 1980;71:637-43.
41. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-6.
42. Lévi F, Misset J-L, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel progammable pump. Cancer 1992;69: 893-900.
43. Massari C, Brienza S, Rotarski M. Oxaliplatin Transplatin® comparative pharmacokinetics in normal and impaired renal function patients [abstract]. Proc Am Assoc Cancer Res 1994;35:242.
44. Brienza S, Vignoud J, Itshaki M, Krikorian A, Oxaliplatin (L-OHP®): global safety in 682 patients [abstract]. Proc Am Soc Clin Oncol 1995;14:209.
45. Lévi F, Zidani R, Vannetzel J-M, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994;86:1608-17.
46. Giacchetti S, Zidani R, Perpoint B, Pinei MC, Faggiuolo R, Focan C, et al. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) [abstract]. Proc Am Soc Clin Oncol 1997;16:229a.
47. Diaz-Rubio E, Zaniboni A, Gastiaburu J, Labianca R, CortesFunes H, De Braud F, et al. Phase II multicentric trial of oxaliplatin as first line chemotherapy in metastatic colorectal carcinoma [abstract]. Proc Am Soc Clin Oncol 1996;15: 207.
48. Becouarn Y, Ychou M, Ducreux M, Borel C, BertheaultCvitkovic F, Seitz JF, et al. Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report [abstract]. Proc Am Soc Clin Oncol 1997;16:229a.
49. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-8.
50. Lévi F, Perpoint B, Garufi C, Focan C, Chollet P, DepresBrummer P, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993;29A:1280-4.
51. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Depres-Brummer P, Brienza S, Adam R, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996;14:2950-8.
52. De Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48h-continuous infusion in pre-treated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
53. Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in CRC. Eur J Cancer 1995; 31A:1277-82.
54. Cunningham D, Zalcberg J, Smith I, Gore M, Pazdur R, Burris H, et al. A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 1996;7:179-82.
55. Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996;14:1495-503.
56. Sorensen JM, Jordan E, Grem JL, Arbuck SG, Chen AP, Hamilton JM, et al. Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase [abstract]. Ann Oncol 1994;5(Suppl.5):132.
57. Pazdur R, Vincent M. Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial [abstract]. Proc Am Soc Clin Oncol 1997;16:228a.
58. Harper P. Advanced colorectal cancer (ACC): results from the latest raltitrexed Tomudex® (raltitrexed) comparative study [abstract]. Proc Am Soc Clin Oncol 1997;16:228a.
59. Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, et al. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996;14:716-21.
60. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996;7: 961-5.
61. Twelves C, Budman DR, Creaven PJ, Schellens JHM, Kuruma I, Dumont E, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase 1 studies [abstract]. Proc Am Soc Clin Oncol 1996;15:476.
62. Cao S, Lu K, Ishitsuka H, Rustum YM. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors [abstract]. Proc Am Soc Clin Oncol 1997;16:226a.
63. Ishikawa T, Sawada N, Sekiguchi F, Fukase Y, Ishitsuka H. Xeloda™ (capecitabine), a new oral fluoropyrimide carbamate with an improved efficacy profile over other fluoropyrimidines [abstract]. Proc Am Soc Clin Oncol 1997;16: 226a.
64. Meropol NJ, Budman DR, Creaven PJ, Lichtman S, Berghorn E, Behr J, et al. A phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors [abstract]. Ann Oncol 1996; 7(Suppl 1):87.
65. Taguchi T, Ishitani K, Saitoh K, Kurihara M, Tominaga T, Fukuyama Y, et al. A Japanese phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors [abstract]. Ann Oncol 1996;7(Suppl 1):87.
66. Hughes M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, et al. A phase I study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer [abstract]. Ann Oncol 1996;7(Suppl 1):87.
67. Dirix LY, Bissett D, van Oosterom AT, Allman DS, Osterwalder B, Cassidy J, et al. A phase 1 study of capecitabine in combination with oral leucovorin in patients with advanced and/or metastatic solid cancer [abstract]. Ann Oncol 1996; 7(Suppl 5):124.
68. Findlay M, van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, et al. A randomised phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:227a.
69. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-300.
70. Ansfield FJ, Kallas GJ, Singson JP. Phase I-II studies of oral tegafur (Ftorafur). J Clin Oncol 1983;1:107-10.
71. Fujii S, Kitano S, Ikenaka K. Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother 1979;6:377-84.
72. Muggia FM, Wu X, Spicer D, Groshen S, Jeffers S, Leichman CG, et al. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 1996;2:1461-7.
73. Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs 1996;7:728-33.
74. Ho DH, Pazdur R, Brown N, Covington W, Lin J, Rustum Y, et al. Clinical pharmacology of oral uracil and ftorafur (4:1 molar ratio) + oral leucovorin [abstract]. Proc Am Assoc Cancer Res 1993;34:396.
75. González-Barón M, Feliu J, Ordonez A, Colmenarejo A, Espinosa E, Zamora P, et al. Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal. Anticancer Res 1993;13:759-62.
76. Meropol NJ, Rustum YM, Petrelli NJ. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 1996;37:581-6.
77. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, et al. A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995;75:782-5.
78. González-Barón M, Feliu J, de la Gándara, Espinosa E, Colmenarejo A, Martinez-Martinez B, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995;31A: 2215-19.
79. Feliu J, González-Barón M, Espinosa E, Garcia Giron C, de la Gandara, I, Espinosa J, et al. Uracil and tegafur modulated with leucovorin. An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 1997;79:1884-9.
80. Cao S, Rustum YM, Shirasaka T, Taguchi T. A new 5-fluorouracil prodrug, S-1 orally bioavailable with high therapeutic index in model system active in Phase II clinical trials [abstract]. Proc Am Soc Clin Oncol 1997;16:227a.
81. Peters GJ, Van Groeningen CJ, Schornagel JH, Gall HE, Noordhuis P, de Vries M, et al. Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU)-based antineoplastic agent [abstract]. Proc Am Soc Clin Oncol 1997;16:227a.
82. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6.
83. Taguchi T, Shirasaka T. New oral anticancer agent: S-1 [abstract]. Ann Oncol 1996;7(Suppl 1):66.
84. Cao S, Shirasaka T, Rustum YM. Simultaneous inhibition of phosphoribosyl pyrophosphate transferase (PRPPT) and dihydropyrimidine dehydrogenase (DPD) enhances the therapeutic selectivity of Tegafur, a 5-fluorouracil prodrug, alone and in combination with cisplatin (CDDP) [abstract]. Proc Am Assoc Cancer Res 1996;37:288.
85. Rustum YM, Cao S, Shirasaka T, Taguchi T. A new 5-fluorouracil prodrug, S-1 orally bioavailable with high therapeutic index in model system active in phase II clinical trials [abstract]. Proc Am Soc Clin Oncol 1997;16:227a.
86. O'Dwyer PJ, DeLap RJ, King SA, Gríllo-Lopez AJ, Hoth DF, Leyland-Jones B. Trimetrexate: clinical development of a nonclassical antifolate. Monogr Natl Cancer Inst 1987;5:105-9.
87. Romanini A, Li WW, Colofiore JR, Bertino JR. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but methotrexate/fluorouracil, in CCRF-CEM cells. J Natl Cancer Inst 1992;14:3085-96.
88. Ajani JA, Abbruzzese JL, Faintuch JS, Patt YZ, Boman BM, Jackson DE, et al. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest 1990;8: 619-21.
89. Brown TD, Fleming TR, Goodman PJ, MacDonald JS, Pugh RP, O'Rourke T. A randomised trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group Study. Anticancer Drugs 1995;6:219-23.
90. Grochow L, Noe D, Dole G, Rowinsky RK, Ettinger DS, Graham ML, et al. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 1989;81:124-30.
91. Elliot WL, Howard CT, Dykes DJ, Leopold WR. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res 1989;49: 5586-90.
92. Conti JA, Kemeny N, Seiter K, Goker E, Tong W, Andre M, et al. Trial of sequential trimetrexate, fluorouracil and high dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994;12:695-700.
93. Blanke C, Kasimis B, Schein P, Capizzi R, Kurman M. Phase II study of trimetrexate, fluorouracil and leucovorin for advanced colorectal cancer. J Clin Oncol 1997;15:915-20.
94. Kreuser ED, Szelenyi H, Hohenberger P, Lochs H, Habboubi N, Oster W, et al. Trimetrexate, 5-fluorouracil and folinic acid: an effective regimen in previously untreated patients with advanced colorectal carcinoma [abstract]. Proc Am Soc Clin Oncol 1997;16:294a.
95. Baccanari DP, Davis ST, Knick VC, Spector T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993;90:11064-8.
96. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54:1507-10.
97. Schilsky RL, Burris H, Ratain M, VonHoff D, Janisch L, Smetzer L, et al. Phase I clinical and pharmacologic study of 776C85 (776) plus 5-fluorouracil (FU) in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol 1996;15: 485.
98. Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996;14:3085-96.
99. Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980;40:717-21.
100. Mellstedt H, Frödin J-E, Biberfield P, Fagerberg J, Giscombe R, Hernandez A, et al. Patients treated with monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the "internal image of the antigen" (ab2). Int J Cancer 1991;48:344-9.
101. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm AL, Mellstedt H, Frodin JE. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 1996;42:81-7.
102. Ragnhammar P, Fagerberg J, Frodin JE, Hjelm AL, Lindemalm C, Magnusson I, et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int J Cancer 1993;53:751-8.
103. Ragnhammar P, Fagerberg J, Frodin JE, Wersall P, Hansson LO, Mellstedt H. Granulocyte/macrophage-colony stimulating factor augments the induction of antibodies, especially anti-idiotypic antibiotics, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 1995;40:367-75.
104. Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A.II. Pharmacokinetics and immune response. J Natl Cancer Inst 1988;80:937-42.
105. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343:1177-83.
106. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al. Monoclonal antibody therapy for resected Dukes C colorectal cancer: 7-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
107. Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, et al. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 1996;14: 729-36.
108. Goldberg RM, Moertel CG, Wieand HS, Krook JE, Schutt AJ, Veeder MH, et al. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer 1995;76: 961-5.
109. Punt CJA, Humblet Y, Roca E, Dirix LY, Wainstein R, Polli A, et al. Tallimustine in advanced previously untreated colorectal cancer, a phase II study. Br J Cancer 1996;73:803-4.
110. Clamon GH, Riggs CE, Dreicer R, Hohl RJ. Phase II trial of edatrexate in patients with metastatic colorectal cancer. Invest New Drugs 1996;13:359-61.
111. Joffe JK, Perren TJ, Bradley C, Primrose J, Hallam S, Ward U, et al. A phase II study of recombinant interferon-beta (rhlFN-β 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Br J Cancer 1997;75:423-6.
112. Arbuck SG, Christian MC, Fisherman JS, Cazenave LA, Sarosy G, Suffness M, et al. Clinical development of Taxol. Monogr Natl Cancer Inst 1993;15:11-24.
113. Sternberg CN, Ten Bokkel Huinink WW, Smyth JF, Bruntsch V, Dirix LY, Pavlidis NA, et al. Docetaxal (Taxotere™), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study. Br J Cancer 1994;70:376-9.
114. Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, et al. Phase II trial of docetaxel (Taxotere®) in the metastatic colorectal carcinoma. Ann Oncol 1994;5:468-70.
115. Moore DF, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese JL. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 1992;10:323-5.